Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revelation Biosciences Inc (NQ: REVB )

0.9076 +0.0076 (+0.84%)
Streaming Delayed Price Updated: 3:35 PM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 86,339
Open 0.9200
Bid (Size) 0.9004 (1)
Ask (Size) 0.9099 (97)
Prev. Close 0.9000
Today's Range 0.8999 - 0.9299
52wk Range 0.8100 - 25.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results
Via Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase
Via Benzinga

Performance

YTD
-94.07%
-94.07%
1 Month
+5.41%
+5.41%
3 Month
-59.48%
-59.48%
6 Month
-62.03%
-62.03%
1 Year
-95.83%
-95.83%

More News

Read More
Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
From Revelation Biosciences Inc.
Via Business Wire
US Stocks Higher; Target Posts Upbeat Earnings
Via Benzinga
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
Via Benzinga
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
Top 5 Health Care Stocks That Are Preparing To Pump In February
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.